Transcatheter Occlusion Versus Surgery for Patent Ductus Arteriosus: A Five-Year Experience of Treatment Success, Hospital Course and Complications

1998 ◽  
Vol 31 (2) ◽  
pp. 153A
Author(s):  
K Rosen
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Treatment Success ◽  
Transcatheter Occlusion ◽  
Patent Ductus

Clinical Analysis of Thrombocytopenia following Transcatheter Occlusion of a Patent Ductus Arteriosus

Cardiology ◽  
2020 ◽  
pp. 1-5
Author(s):  
Ang Li ◽  
Dan Yin ◽  
Xupei Huang ◽  
Lixin Zhang ◽  
Tiewei Lv ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Clinical Analysis ◽  
Good Prognosis ◽  
Severe Thrombocytopenia ◽  
Residual Shunt ◽  
Transcatheter Occlusion ◽  
High Risk Factors ◽  
Median Diameter ◽  
Patent Ductus

<b><i>Background:</i></b> Our aim is to analyze the correlation between severe thrombocytopenia and the diameter of patent ductus arteriosus (PDA) and residual shunt after PDA closure. <b><i>Methods:</i></b> The patients with severe thrombocytopenia (platelet count &#x3c;50 × 10<sup>9</sup>/L) following transcatheter occlusion of a PDA from January 2010 to December 2018 in the Children’s Hospital of Chongqing Medical University were collected. And the high-risk factors, diagnosis, treatment, and prognosis of severe thrombocytopenia were analyzed. <b><i>Results:</i></b> A total of 1,581 children with transcatheter occlusion of a PDA were collected; 22 (1.39%) of the enrolled patients had severe thrombocytopenia. Further data analysis showed that the median diameter of PDA (6.7 [IQR: 1.63]) mm in children with severe thrombocytopenia was significantly larger than that in children without severe thrombocytopenia (3.6 ± 1.7 mm, <i>p</i> &#x3c; 0.001). Furthermore, the incidence of thrombocytopenia in children with residual shunt after operation (10.9%) was significantly higher than that in children without residual shunt (0.2%, <i>p</i> &#x3c; 0.001). The mean time of thrombocytopenia was found to be 2.4 ± 1.3 days after intervention. All patients with thrombocytopenia were treated by methylprednisolone with or without platelet transfusion and recovered without major organ hemorrhage. <b><i>Conclusions:</i></b> Severe thrombocytopenia following transcatheter occlusion of a PDA may be related to the larger diameter of PDA and residual shunt. If early detection of severe thrombocytopenia is obtained, our study supports a good prognosis if appropriate measures are implemented.

Vascular endothelial growth factor polymorphism rs2010963 status does not affect patent ductus arteriosus incidence or cyclooxygenase inhibitor treatment success in preterm infants

2019 ◽  
Vol 29 (7) ◽  
pp. 893-897
Author(s):  
Hannes Sallmon ◽  
Tünay Aydin ◽  
Stefanie Hort ◽  
Anja Kubinski ◽  
Christina Bode ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Treatment Success ◽  
Vascular Endothelial ◽  
Cyclooxygenase Inhibitor ◽  
Endothelial Growth Factor ◽  
Inhibitor Treatment ◽  
Patent Ductus

AbstractBackground:Vascular endothelial growth factor is critically involved in ductus arteriosus closure. Polymorphisms in the vascular endothelial growth factor gene have been associated with several diseases in neonates and adults.Aim:Herein, we investigated if vascular endothelial growth factor polymorphism rs2010963 status is associated with patent ductus arteriosus incidence and/or pharmacological treatment success.Methods:We assessed rs2010963 status in 814 preterm infants (<1500 g birth weight) by means of restriction fragment length polymorphism analysis. DNA samples were obtained from dry-spot cards used for the German national newborn screening program. Clinical data were obtained by retrospective chart review.Results:We could not find any statistically significant difference in the incidence of patent ductus arteriosus depending on vascular endothelial growth factor rs2010963 polymorphism status. Furthermore, no statistically significant associations between vascular endothelial growth factor polymorphism rs2010963 status and cyclooxygenase inhibitor treatment success were observed.Conclusion:Our results indicate that there is no association between vascular endothelial growth factor polymorphism rs2010963 status and the occurrence of patent ductus arteriosus or the response to cyclooxygenase inhibitor treatment in a large cohort of preterm infants. Additional studies are needed to determine the role of genetic factors on patent ductus arteriosus incidence and treatment response.

Transcatheter occlusion of patent ductus arteriosus using coil embolization

1997 ◽  
Vol 60 (2) ◽  
pp. 133-138 ◽  
Author(s):  
José Luiz B Jacob ◽  
Wilson M.C Coelho ◽  
Nilton C.S Machado ◽  
Sérgio A.C Garzon
Keyword(s):  
Patent Ductus Arteriosus ◽  
Coil Embolization ◽  
Ductus Arteriosus ◽  
Transcatheter Occlusion ◽  
Patent Ductus

Transcatheter occlusion of the patent ductus arteriosus: a comparison of two devices

2002 ◽  
Vol 171 (3) ◽  
pp. 151-154
Author(s):  
M. K. El Mallah ◽  
A. J. Sands ◽  
F. A. Casey ◽  
B. G. Craig ◽  
H. C. Mulholland
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Transcatheter Occlusion ◽  
Patent Ductus

scholarly journals Transcatheter Occlusion of Patent Ductus Arteriosus in Pre-Term Infants

2010 ◽  
Vol 3 (5) ◽  
pp. 550-555 ◽  
Author(s):  
Edwin Francis ◽  
Anil Kumar Singhi ◽  
Srinivas Lakshmivenkateshaiah ◽  
Raman Krishna Kumar
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Term Infants ◽  
Transcatheter Occlusion ◽  
Patent Ductus

A novel approach to ductal spasm during percutaneous device occlusion of patent ductus arteriosus

2015 ◽  
Vol 26 (7) ◽  
pp. 1352-1358 ◽  
Author(s):  
Rik De Decker ◽  
George Comitis ◽  
Jenny Thomas ◽  
Elmarie van der Merwe ◽  
John Lawrenson
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Prostaglandin E ◽  
Total Intravenous Anaesthesia ◽  
Intravenous Anaesthesia ◽  
Transcatheter Occlusion ◽  
Novel Approach ◽  
Complete Relaxation ◽  
Induction Of Anaesthesia ◽  
Patent Ductus

AbstractDuctal spasm is a rare yet important complication of device occlusions of patent ductus arteriosus. Spasm may result in failure of the procedure, under-sizing of the device, or embolisation of the implanted device as the spasm resolves after the procedure. We describe a novel protocol that rapidly and completely reversed the spasm in eight prematurely born infants who experienced ductal spasm during cardiac catheterisations for patent ductus arteriosus occlusion.In total, eight infants born between 25 and 34 weeks of gestation presented for transcatheter patent ductus arteriosus occlusion between 13 and 87 months of age. All eight patients experienced ductal spasm either immediately before, during, or soon after induction of anaesthesia or only after entering the ductus arteriosus with a catheter. After detection of the spasm, the anaesthetist, in each case, changed the mode of anaesthesia from inhaled sevoflurane to total intravenous anaesthesia with propofol, reduced the inhaled oxygen fraction to 21%, and initiated a continuous intravenous infusion of prostaglandin E1.The first two steps (total intravenous anaesthesia and FiO2 0.21) resulted in only partial relaxation of the spasm. Complete relaxation was attained after intravenous prostaglandin E1 infusions of only 10–15 minutes’ duration. While maintaining this protocol, six ducti were successfully occluded and two were considered to be unsuitable for device occlusion and were referred for surgery.Ductal spasm during transcatheter occlusion may be reliably resolved and the procedure safely completed by a simple anaesthetic protocol, including the continuous infusion of intravenous prostaglandin E1.

Transcatheter occlusion of the patent ductus arteriosus in premature infants weighing less than 1200 g

2017 ◽  
Vol 103 (3) ◽  
pp. F198-F201 ◽  
Author(s):  
Patrice Morville ◽  
Stephanie Douchin ◽  
Helene Bouvaist ◽  
Claire Dauphin
Keyword(s):  
Patent Ductus Arteriosus ◽  
Premature Infants ◽  
Transcatheter Closure ◽  
Ductus Arteriosus ◽  
Left Pulmonary Artery ◽  
Transcatheter Occlusion ◽  
Alternative Means ◽  
The Mean ◽  
Pulmonary Artery Obstruction ◽  
Patent Ductus

ObjectivesOver the last few decades different strategies have been proposed to treat persistent ductal patency in premature infants. The advent of the Amplatzer Duct Occluder II Additional Size (ADOIIAS) provided the potential to close the patent ductus arteriosus (PDA). Opinions differ on the significance and treatment of PDA in premature neonates. Because surgical ligation and medical therapy both have their drawbacks, interventional catheterisation can be considered as an alternative means of closing the ductus arteriosus. Our aim was to analyse the feasibility, safety and efficacy of this device in premature infants weighing <1200 g at procedure.MethodsEighteen premature infants underwent transcatheter closure. The procedure was performed in the catheterisation laboratory by venous cannulation without angiography. The position of the occluder was directed by X-ray and ultrasound. We looked at procedural details, device size selection, complications and short-term and mid-term outcomes.ResultsEighteen infants born at gestational ages ranging between 23.6 and 29+6 weeks (mean±SD 25+6±3 weeks) underwent transcatheter PDA closure. Their mean age and weight at the time of the procedure was 20 days (range 8–44 days) and 980 g (range 680–1200 g), respectively. The mean PDA and device waist diameters were 3.2±0.6 mm (range 2.2–4 mm) and 4.5±0.6 mm, respectively, and the mean PDA and device lengths were 4.3±1.2 mm (range 2–10 mm) and 2.5±0.9 mm, respectively. Complete closure was achieved in all but one patient. There was no device migration. One patient developed a left pulmonary artery obstruction. Three infants died. Two deaths were related to complications of prematurity and one to the procedure.ConclusionsTranscatheter closure of a PDA is feasible in very low weight infants with ADOIIAS and is an alternative to surgery. Success requires perfect selection and placement of the occluder.

Sign in / Sign up

Export Citation Format

Share Document